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the older method. Potential for drug accumulation was more
readily apparent in the simulated data using the new formu-
las. The spreadsheets used for the two methods appeared
practically identical.
Conclusion: Consideration should be given to using these
AUC formulas and adjusted targets unless all infusions are
given strictly over 30min.
doi:10.1016/j.ijid.2008.05.1080
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Background: There are no published information on tige-
cycline potency and spectrum from isolates from Indonesia.
As a component of the SENTRY Antimicrobial Surveillance
Program (Asia-Paciﬁc Region), we evaluated the activity
of tigecycline tested against recent (2006) isolates from
Indonesia by reference MIC methods.
Methods: Non-duplicate strains were consecutively col-
lected from three medical centres in Indonesia. All isolates
were tested against tigecycline using validated commercial
broth microdilution panels (TREK Diagnostics), with con-
current acceptable quality control and CLSI interpretations
(M100-S18) for comparison agents. Tigecycline breakpoints
published by the United States - Food and Drug Adminis-
tration were applied for each indicated species or genus,
and the proposed/provisional Acinetobacter spp. breakpoint
(≤2mg/L) per Jones et al. (2007) was applied
Results: A total of 383 (307 Gram-negative and 76 Gram-
positive) isolates were evaluated. Tigecycline was highly
active against the top 10 most frequently isolated non-
pseudomonal pathogens which comprised 82% of all strains.
The highest tigecycline MIC90 results (2mg/L were recorded
for non-indicated species, Proteus-Providencia. P. aerug-
inosa was also not signiﬁcantly inhibited by tigecycline
(MIC90, >8mg/L; data not shown)
Conclusions: Tigecycline demonstrated excellent activity
against all the commonly isolated pathogens from Indonesia,
including those being multidrug-resistant to other antimi-
crobial classes. Tigecycline shows promise for therapy of
indicated, antimicrobial-resistant species in this nation and
indeed, the entire Asia-Paciﬁc region.
doi:10.1016/j.ijid.2008.05.1081
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Background: Tigecycline is a glycylcycline class agent
recently introduced into clinical practice worldwide as an
alternative therapy for various evolving multidrug-resistant
(MDR) bacterial infections. China, Hong Kong (HK) and Tai-
wan medical centers (14) were monitored in 2006 by the
SENTRY Program for tigecycline spectrum/susceptibility and
compared to more than 25 agents.
Methods: CLSI methods were used for testing 2,595 iso-
lates with US-FDA (tigecycline product package insert) and
CLSI (M100-S18) breakpoints applied. Resistance phenotypes
were screened per CLSI M100-S18 and genotypic-resistances
by sequencing when required. Tigecycline was not active
against P. aeruginosa (MIC50, >4g/ml), data not shown
Results: Among 2,595 strains processed, the most fre-
quently tested pathogens and resistance patterns were:
S. aureus (545, 40% MRSA) > E. coli (366, 52% ESBL)>
K. pneumoniae (265, 33% ESBL) > E. faecalis (218,
linezolid resistance detected) > A. baumannii (211,
29% carbapenem-resistant) >S. pneumoniae (175, 27/80%
penicillin/macrolide-resistant) > E. faecium (169, 2.4%
VanA-type glycopeptide resistance). Fluoroquinolone resis-
tance was very high among E. coli (64%), K. pneumoniae
(21%) and A. baumannii (62%). MRSA rates varied by
nation: Hong Kong and China (38%) and Taiwan (69%),
but oxacillin resistance did not effect tigecycline activ-
ity. Metallo--lactamases were noted in Enterobacteriaceae
(<1%). Tetracycline resistance was frequent (30—86%) in
Gram-positive and -negative organisms; but no tigecycline-
resistant or non-susceptible strains were detected among
indicated species except for enterococci (2.3%)
Conclusions: Tigecycline retained high activity and treat-
ment potential against MDR pathogens tested from China,
Hong Kong and Taiwan. Continued monitoring of the tigecy-
cline class agents in these nations appears prudent as the
glycylcyclines become widely used.
doi:10.1016/j.ijid.2008.05.1082
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Background: Tigecycline has been marketed in Australia
for over one year. As part of the SENTRY Antimicrobial
Surveillance Program (Asia-Paciﬁc Region), we evaluated the
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activity of tigecycline against recent (2006) bacterial iso-
lates across Australia.
Methods: Non-duplicate strains were consecutively col-
lected from ﬁve medical centres in 5 states using isolates
from bacteraemia (n = 253), pneumonia (n = 146), compli-
cated skin and skin structure infections (n = 264), and
other infections (n = 269). All isolates were tested against
tigecycline using validated commercial reference broth
microdilution panels (TREK Diagnostics), with concurrent
quality controls and CLSI (M100-S18) interpretations for
comparison agents. Tigecycline breakpoints published by the
US-FDA were applied for each indicated species or genus
group.
Results: A total of 932 (268 Gram-negative and 664
Gram-positive) isolates were processed. Tigecycline was
highly active against the top 10 non-pseudomonal pathogens
which comprised 88% of all tested isolates. Tigecycline
MIC90 results ranged from ≤0.12 to 1mg/L, highest for
Klebsiella spp. and Proteae (data not shown). At US-FDA
published breakpoints, tigecycline exhibited complete inhi-
bition of indicated species except for a single strain of E.
cloacae (MIC, 4mg/L). Over 28% of Staphylococcus aureus
were oxacillin-resistant, and one Enterococcus faecium
was vancomycin-resistant. Tigecycline was highly effective
against these strains.
Conclusions: Tigecycline has potent activity against all
the common pathogens isolated in 2006 from Australian
patients, including those resistant to other drug classes.
Documented acquired resistance was rare among indicated
pathogens, however, Pseudomonas remains refractory to
potential tigecycline therapy.
doi:10.1016/j.ijid.2008.05.1083
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Objectives: Worldwide the prevalence of MDR Enter-
obacteriaceae are increasing, including ESBLs, AmpC,
ﬂuoroquinolone and carbapenem resistant strains. The
T.E.S.T. program determined the in vitro activity of tigecy-
cline compared to amoxicillin-clavulanic acid, piperacillin-
tazobactam, levoﬂoxacin, ceftriaxone, cefepime, ampi-
cillin, amikacin, minocycline, ceftazidime and imipenem
against Enterobacteriaceae species collected from hospi-
tals in Asia/Paciﬁc Rim 2004—2007. This study evaluated
the activity of tigecycline against multi-resistant microor-
ganisms associated with nosocomial infections.
Methods: A total of 2778 clinical isolates were identiﬁed
to the species level at each site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentration (MICs) were
determined by each site using supplied broth microdilution
panels and interpreted according to CLSI guidelines. Tigecy-
cline breakpoint is deﬁned as susceptible MICs ≤2mcg/mL
Results: The table illustrates the %S and MIC90 of tigecy-
cline to MDR pathogens
Conclusions: Multi-drug resistance is common in health
care acquired pathogens. The presented data indicate that
tigecycline is highly potent against nosocomial pathogens
including MDR isolates.
doi:10.1016/j.ijid.2008.05.1084
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Objectives: Tigecycline (TIG) is a new glycylcycline with
enhanced activity against many multidrug resistant (MDR)
pathogens including ESBL and AmpC producing Enterobacte-
riaceae, methicillin-resistant S. aureus (MRSA), carbapenem
resistant Acinetobacter and ﬂuoroquinolone resistant gram-
negative rods. The TEST study evaluated the activity of TIG
and comparators to pathogens in Canada 2004—2007.
Methods: A total of 1675 pathogens were collected from 8
participating sites in Canada from 2004—2007. Isolates were
identiﬁed to the species level and CLSI speciﬁed MICs were
performed at each site. CLSI or FDA breakpoints were used,
where applicable, to determine % susceptibility
Results: Tigecycline MICs are recorded in the table below
Conclusions: Tigecycline showed excellent in vitro activ-
ity against a diverse collection of pathogens isolated in
Canada between 2004—2007. MIC90 values of 0.5mcg/ml
against most Enterobacteriaceae including ESBL and MIC90
of ≤0.12mcg/ml against gram-positive pathogens document
the in vitro potency of tigecycline, a new glycylcycline.
doi:10.1016/j.ijid.2008.05.1085
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Aim: To assess the antimicrobial resistance patern in
pathogens responsible for urinary tract infections in noso-
comial patients over a period of one year.
Material and Method: From January 2006 to Decem-
ber 2006, 3665 urine cultures from nosocomial patients
were collected. All positive cultures with a colony count
≥105CFU/ml for Gram-positive and Gram-negative bacte-
ria and ≥103CFU/ml for Candida species were selected for
the analysis. Duplicate isolates were not considered
Results: Among the 757 positive cultures n = 135 belonged
to I.C.U., n = 58 to Surgical Dept, n = 347 to Internal Medicine
Dept and n = 217 to Outpatien Dept. Among the 757 pos-
itive cultures n = 523 belonged to female and n = 234 to
